Utility of Routine Intraoperative Ureteral Frozen Section Analysis at Radical Cystectomy: Outcomes from a Regional Australian Center

Joanne Tang\textsuperscript{a} Weranja Ranasinghe\textsuperscript{b} Janice Cheng\textsuperscript{b} Sabiena Van Es\textsuperscript{b}
Mike Monsour\textsuperscript{b} Richard Cetti\textsuperscript{b} Robert Jensen\textsuperscript{b} Steve Brough\textsuperscript{b}
\textsuperscript{a}University of Tasmania; \textsuperscript{b}Launceston General Hospital, Launceston, TAS, Australia

Key Words
Frozen section • Ureter • Cystectomy • Mortality • Cost effectiveness

Abstract

Introduction: The objective of this study was to look at the usefulness and cost effectiveness of intraoperative frozen section analysis (FSA) of the ureters at the time of radical cystectomy. Methods: Pathology notes of patients undergoing radical cystectomy for primary bladder cancer between the years 2000–2015 at our institution were reviewed. Results: A total of 196 ureteric specimens from 98 patients were reviewed. Of the 98 patients, 9\% (n = 9) had positive ureteric margins, of which all were ≥ T2, with 44\% (4 of 9) being T = 4. In all cases of positive FSA, preoperative clinical staging was ≥ T2. In cases where cancer staging was upgraded post-cystectomy, there were no cases of positive FSA. After adjusting for tumor stage in ≥ T2a, using Cox regression analysis, positive frozen section was associated with a 4.2 fold increase in overall mortality (95\%CI 1.3–13.8; p = 0.02). Cost associated with FSA was AUS$1,351.90 to obtain 1 positive result. Conclusion: Patients with positive ureteric FSA are at higher risk of mortality post cystectomy, despite excision to negative tissue. However, FSA of the distal ureters at cystectomy were unlikely to be positive unless the bladder cancer stage was ≥ T2. Hence, routine ureteric FSA may not be necessary in patients undergoing cystectomy for non-muscle invasive bladder tumors.

Introduction

Bladder cancer is a commonly occurring cancer within the Australian population, being the fourth most common solid organ tumor in men, and seventh in women [1]. Radical cystectomy is the treatment of choice in high-risk bladder cancer.

The European Association of Urology guidelines in 2011 recommended the use of intraoperative frozen section analysis (FSA) of ureters during radical cystectomy [2]. However, the influence of intraoperative FSA during radical cystectomy on intraoperative management, prognosis and cost remains a topic of much debate. It adds both a physical burden to the patient, with longer operating time and anesthesia time, as well as economic burden to the health system. Some studies suggest no overall clinical difference in outcome [3]. As such, the current EAU guidelines do not include the use of intraoperative FSA [4]. However, many regional centers in Australia continue to routinely send distal ureters for FSA at the time of cystectomy mainly owing to prognosis and long-term follow-up of regional patients, where some patients have limited access to healthcare. To our knowledge, there are no studies investigating this routine practice and its cost effectiveness in regional Australian centers.

As such, we aimed to investigate the usefulness and cost effectiveness of intraoperative FSA of the ureters at the time of radical cystectomy at a regional hospital in Australia.
Routine Intraoperative Ureteral Frozen Section

**Table 1. Histological characteristics of radical cystectomy specimens**

| Pathological stage | Frequency | Percent (%) |
|--------------------|-----------|-------------|
| T0, Tx             | 12        | 12          |
| CIS                | 6         | 6           |
| Ta                 | 1         | 1           |
| T1                 | 7         | 7           |
| T2                 | 34        | 33          |
| T3                 | 24        | 24          |
| T4                 | 14        | 14          |
| Soft tissue margin |           |             |
| Positive           | 27        | 28          |
| Negative           | 71        | 72          |
| Ureteric margin    |           |             |
| Positive           | 9         | 9           |
| Negative           | 89        | 91          |
| Urethral margin    |           |             |
| Positive           | 19        | 19          |
| Negative           | 63        | 64          |
| Not reported       | 16        | 16          |
| Lymphovascular invasion |   |             |
| Positive           | 44        | 45          |
| Negative           | 54        | 55          |

**Table 2. Frozen section positivity according to pathological staging**

| Stage | Number (%) | FS positive (%) |
|-------|------------|-----------------|
| T0, Tx| 12 (12)    | 0 (0)           |
| CIS   | 6 (6)      | 0 (0)           |
| Ta    | 1 (1)      | 0 (0)           |
| T1    | 7 (7)      | 0 (0)           |
| T2    | 34 (33)    | 3 (9)           |
| T3    | 24 (24)    | 1 (4)           |
| T4    | 14 (14)    | 5 (36)          |

**Table 3. Preoperative pathological staging, with subsequent up- and down-staging**

| Preoperative staging | Frequency (%) | Up-staged (%) | Down-staged (%) |
|----------------------|---------------|---------------|-----------------|
| CIS                  | 12 (12)       | 4 (33)        | 1 (8)           |
| Ta                   | 1 (1)         | 0 (0)         | 0 (0)           |
| T1                   | 13 (13)       | 5 (38)        | 3 (23)          |
| T2                   | 51 (52)       | 16 (31)       | 9 (18)          |
| T3                   | 15 (15)       | 0 (0)         | 5 (33)          |
| T4                   | 5 (5)         | 0 (0)         | 1 (20)          |

Chi-squared analysis was performed to compare FSA positivity of distal ureters with gender, age, stage, tumor, grade, nodal status, concomitant CIS and ureteric involvement. A cox-proportional hazard analysis for risk factors was performed. Finally, a cost-analysis was also performed based on 2015 fees. SPSS statistical software (version 17.0) was used for statistical analysis.

**Results**

Over the years 2000–2015, a total of 116 patients underwent cystectomy at our center of which 102 patients had a cystectomy for primary bladder cancer. Four of the patients had missing data and were excluded from the analysis, resulting in 98 patients in the final analysis. The total number of urologists involved were 6, with 2 primary pathologists reporting the results. Male to female patient ratio was 67:31 (2:1). Mean length of follow-up was 70 months. Four patients had neoadjuvant chemotherapy in our regional center for the duration of the study. The adjuvant chemotherapy data was not available.

Histology of the specimens showed 92 urothelial carcinomas, 5 small cell carcinomas, and 1 neuroendocrine tumor. Histological features of the specimens including distribution of tumor stages are summarised in table 1. All patients undergoing radical cystectomy had ureters sent for frozen section, of which 9% (n = 9) samples were positive on frozen section. In all cases of positive frozen section ureteric margins, pathological staging was ≥ T2, with the greatest frequency of positive margins seen in T4 (n = 5), as shown in table 2. Of the 9 patients with positive frozen sections, 3 had CIS at the margin and the rest urothelial carcinoma.

Preoperative biopsy was also considered as a possible predictor of ureteral FSA positivity. One patient had preoperative clinical data missing. Distribution of preoperative staging, and subsequent upstaging and downstaging post-cystectomy is in table 3. Of the 97 patients, 27 had a preoperative stage of < T2; of whom 0 subsequently had a positive ureteric margin on FSA. Of remainder 71 patients...
patients who had a preoperative stage of ≥ T2, 9 subsequently had a positive ureteric margin on FSA. Of the 9 cases of < T2 that eventually upgraded to ≥ T2, 0 had a positive ureteric FSA (table 4).

Of the 9 patients with concomitant or primary CIS, none had positive ureteric margin on FSA. After adjusting for tumor stage in ≥ T2a, nodal positivity, metastases and positive soft tissue margins using Cox regression analysis, positive frozen section was associated with a 4.2 fold increase in overall mortality (95%CI 1.3–13.8; p = 0.016) (table 5). Ureteric FS positivity was not involved in positive lymph nodes (p > 0.05).

Cost analysis was performed on ureteric FSA. Based on 2015 Medicare fees, FSA of both ureters cost AU$ 245.80. The total amount spent on FSA for CIS/T1 bladder tumors was AU$ 6,390.80. Total amount spent on FSA for ≥ T2 bladder tumors was AU$ 17,697.60. It requires 9 FSAs to detect 1 positive result, costing AU$ 2,236.80 to detect 1 positive result. If limited to ≥ T2 bladder tumors, it requires only 7 frozen sections to detect 1 positive result, and the cost decreases to AU$ 1,351.90 to detect 1 positive result.

**Discussion**

Current practice guidelines recommend the use of radical cystectomy with pelvic lymph node dissection as the treatment option for non-metastatic, muscle invasive bladder cancer. EAU guidelines also recommend the use of FSA of the ureters at the time of surgery [2, 5]. However, the use of ureteric FSA at the time of surgery remains a point of much debate [6–9].

Our results find that while positive ureteric margins is associated with poorer overall survival; incidence of positive margins was fairly low (9%, n = 9), with the incidence of positive ureteric margins being 0 in patients with a preoperative pathological stage of T < 2, even if they were up-staged postoperatively. Even in cases with concurrent CIS, ureteric margins remained negative in all cases. These results would suggest the selective use of ureteric FSA in patients with a preoperative pathological staging of ≥ T2a only.

Our findings are consistent with several other studies conducted across the world. Several studies place the incidence of positive ureteric margins on FSA at 4–15% [10–12]. Similarly, ureteric margin positivity has not been shown to be associated with lymph node positivity [13]. Sensitivity of intraoperative FSA has been shown to be quite variable 45–80%; while specificity has always remained high at 95–99% [10].

Other studies have also shown that while positive ureteric margins on FSA has been associated with upper urinary tract recurrence, it has not been associated with poorer disease-specific survival rates [7, 13, 14]. This is in contrast to our results that support the use of ureteric positivity as a predictor of poorer overall survival rates. However, it should be kept in mind that our study did not look at upper urinary tract recurrence and disease-specific survival.

It’s also been suggested that upper urinary tract recurrence may be more prone to occur in patients with cancer involvement at the intramural or juxtavesical ureter [15, 16], or in patients with CIS of the bladder [3, 17]; with ureteric positivity being an associated but non-independent risk factor for recurrence.

Practical concerns to consider include the risk of uretero-enteric anastomotic recurrence in patients with positive ureteric margins. Several studies have observed rates of anastomotic recurrence of about 0–1%, despite the presence of CIS or urothelial cancer in 14% of nephron-ureterectomy specimens [3, 15]. While these rates are low, the effect of frozen section guided resection cannot be determined. However, it should also be considered that even in the presence of negative margins, uretero-enteric recurrence can still occur.

Our cost analysis places the cost of obtaining one positive result at AU$ 2,236. Few studies have looked at the

| Variable                      | Hazard ratio | 95%CI      | p     |
|-------------------------------|--------------|------------|-------|
| T stage: > T2                 | 4.6          | 1.9–11.4   | 0.001 |
| Nodal positivity: ≥ 1         | 1.5          | 0.9–2.7    | 0.142 |
| Metastases: ≥ 1               | 0.4          | 0.5–1.5    | 0.353 |
| Positive ureteric margin      | 4.2          | 1.3–13.8   | 0.016 |
| Positive soft tissue margin   | 0.7          | 0.3–2.0    | 0.54  |

* One preoperative clinical data missing.

| Preoperative staging | Number* | Positive ureteric margin on FSA |
|----------------------|---------|---------------------------------|
| T0/CIS/Ta/T1         | 26      | 0 (0)                           |
| ≥ T2                 | 71      | 9 (13)                          |
| T0/CIS/Ta/T1 upgraded to ≥ T2 | 9     | 0 (0)                           |
cost associated with ureteric FSA. Our result was only marginally higher than Touma et al. [18], which reported a cost of CANS 2,080 (equivalent to AU$ 2,100). However, we found that diagnostic yield can potentially be increased by limiting the use of ureteric FSA to patients who are at high risk of ureteral abnormalities, such as in the presence of bladder CIS or in patients with a preoperative staging of ≥ T2a.

Results of this study may be limited by its retrospective nature. Surgical guidelines and practices have improved and changed significantly over the past 15 years. Surgical practices are also likely to vary between surgeons, possibly affecting margin positivity [19]. In addition, this study had a relatively small number of patients, with even fewer numbers having concurrent or primary CIS.

**Conclusion**

Patients with positive ureteric FSA are at higher risk of overall mortality post-cystectomy, despite excising the ureter until a negative segment is achieved. FSA of the distal ureters at cystectomy are however unlikely to be positive unless the bladder cancer stage is ≥ T2. Omitting routine ureteric FSA in patients undergoing cystectomy for non-muscle invasive bladder tumors may therefore provide an economic benefit without impacting on clinical outcome.

**Ethics Approval**

Ethics approval was obtained from the institutional ethics committee. Ethical approval in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**References**

1. McCombie SP, Hayde D: Current trends in bladder cancer in Australia. Trends Urol Men Health 2014;5:16–20.
2. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, Roupé M: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011;59:997–1008.
3. Schumacher MC, Scholz M, Weise ES, Fleischmann A, Thallmann GN, Studer UE: Is there an indication for frozen section examination of the ureteral margins during cystectomy for transitional cell carcinoma of the bladder? J Urol 2006;176:2409–2413.
4. Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, James N, Lebrét T, Sherif A, van der Heijden AG, Ribal MJ: Guidelines on muscle-invasive and metastatic bladder cancer, 2015. Available from: http://uroweb.org/wp-content/uploads/07-Muscle-Invasive-BC_LR.pdf.
5. Witjes JA, Compérat E, Cowan NC, Santis MD, Gakis G, James N: Guidelines on muscle-invasive and metastatic bladder cancer European Association of Urology; 2015.
6. Sureka SK, Yadav A, Arora S, Kapoor R, Mandhani A: Is frozen section analysis of the urethra at the time of radical cystectomy and orthotopic neobladder urinary diversion mandatory? Indian J Urol 2015;31:349–353.
7. Mukha R, Kumar S, Kekre NS: Ureteral frozen section analysis during radical cystectomy: do margins matter? Indian J Urol 2007; 23:211–212.
8. Loeser A, Katzenberger T, Vergho DC, Kocot A, Burger M, Riedmiller H: Frozen section analysis of ureteral margins in patients undergoing radical cystectomy for bladder cancer: differential impact of carcinoma in situ in the bladder on reliability and impact on tumour recurrence in the upper urinary tract. Urol Int 2014;92:50–54.
9. Donat SM: Argument against frozen section analysis of distal ureters in transitional cell bladder cancer. Nat Clin Pract Urol 2008; 5:538–539.
10. Saitkusviam R, Hu B, Metcalfe C, Ghodousipour SB, Aron M, Cai J, Miranda G, Gill I, Daneshmand S: Utility and significance of ureteric frozen section analysis during radical cystectomy. BJU Int 2015;117:463–468.
11. Kim HS, Moon KC, Jeong CW, Kwak C, Kim HH, Ku JH: The clinical significance of intra-operative ureteral frozen section analysis at radical cystectomy for urothelial carcinoma of the bladder. World J Urol 2015;33: 359–365.
12. Hoang AN, Agarwal PK, Walton-Diaz A, Wood CG, Metwalli AR, Kassouf W, Brown GA, Black PC, Urbauer DL, Grossman HB, Dinney CP, Kamar AM: Clinical significance of ureteric ‘skip lesions’ at the time of radical cystectomy: the M.D. Anderson experience and literature review. BJU Int 2014;113:E28–33.
13. Johnson DE, Wishnow KI, Tenney D: Are frozen-section examinations of ureteral margins required for all patients undergoing radical cystectomy for bladder cancer? Urology 1989;33:451–454.
14. Moschini M, Gallina A, Freschi M, Luzzago S, Fossati N, Gandaglia G, Dell’oglio P, Damiano R, Serretta V, Salonia A, Montorsi F, Briganti A, Colombo R: Effect on postoperative survival of the status of distal ureteral margin: The necessity to achieve negative margins at the time of radical cystectomy. Urol Oncol 2016;34:59.e15–22.
15. Neuzillet Y, Soulie M, Larre S, Roupret M, Defortesqu G, Murez T, Pignon G, Descazeaud A, Patard JJ, Bigot P, Salomon L, Collin P, Rigaud J, Bastide C, Durand X, Valeri A, Kleinlauss F, Bruyere F, Pfister C: Positive surgical margins and their locations in specimens are adverse prognosis features after radical cystectomy in non-metastatic carcinoma invading bladder muscle: results from a nationwide case-control study. BJU Int 2013;111:1253–1260.
16. Lee SE, Byun SS, Hong SK, Chang IH, Kim YJ, Gill MC, Song SH, Kim KT: Significance of cancer involvement at the ureteral margin detected on routine frozen section analysis during radical cystectomy. Urol Int 2006; 77:13–17.
17. Sharma TC, Melamed MR, Whitmore WF Jr: Carcinoma in-situ of the ureter in patients with bladder carcinoma treated by cystectomy. Cancer 1970;26:583–587.
18. Touma N, Izawa JJ, Abdelhady M, Moussa M, Chin JL: Ureteral frozen sections at the time of radical cystectomy: reliability and clinical implications. Can Urol Assoc J 2010;4:28–32.
19. Ahmadi N, Delprado WJ, Brooks AJ, Brenner PC, Coombes GM, Grant A, Patel MI: Pathological evaluation and quality of surgery in radical New South Wales, Australia. ANZ J Surg 2015;85:145–149.